Hematologic malignancies
The sponsor is active in clinical research for acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndromes, with interest in treatment strategies used before transplantation and in newly diagnosed disease.
- Acute myeloid leukemia
- Acute lymphoblastic leukemia
- Myelodysplastic syndromes
Its research also includes hematopoietic cell transplantation and remission-focused outcomes in adult blood cancers.
Solid tumors of the head, neck, and skin
Clinical activity covers head and neck squamous cell carcinoma, nasopharyngeal cancer, and advanced non-melanoma skin cancers, including difficult-to-treat squamous and basal cell subtypes.
- Head and neck squamous cell carcinoma
- Nasopharyngeal cancer
- Advanced non-melanoma skin cancer
Research interests include immunotherapy, radiotherapy, and treatment approaches for unresectable or progressive disease.
Sarcomas and rare solid tumors
The sponsor funds studies in soft tissue sarcomas, gastrointestinal stromal tumors, adenoid cystic carcinoma, and adrenocortical carcinoma, reflecting a strong focus on rare and high-risk malignancies.
- Soft tissue sarcomas
- Gastrointestinal stromal tumors
- Adenoid cystic carcinoma
- Adrenocortical carcinoma
There is also interest in metastatic disease, resectable tumors, and adjuvant or preoperative treatment settings.
Breast, prostate, and genitourinary oncology
Research extends to HER2-negative breast cancer and prostate cancer, including patients with locally advanced, recurrent, or metastatic disease.
- HER2-negative breast cancer
- Prostate cancer
- Genitourinary oncology
These studies include interest in radiotherapy, hormone therapy, and disease control after radical treatment.
Supportive care and treatment-related complications
The sponsor also investigates conditions linked to cancer care, including cardiotoxicity, chronic kidney disease, and nicotine dependence in patients with oncologic comorbidity.
- Cardiotoxicity
- Chronic kidney disease
- Nicotine dependence
Additional interest is shown in protecting cardiac function during anthracycline-based treatment and in managing supportive care needs alongside cancer therapy.
